

# TeGenero

<b>Name</b>	<b>TeGenero AG</b>
<b>Address/P.O. Box</b>	<b>Science Park Würzburg Friedrich-Bergius-Ring 15</b>
<b>Postal Code/City</b>	<b>D-97076 Würzburg</b>
<b>State</b>	<b>Bavaria</b>
<b>Contact Person</b>	<b>Dr. Benedikte Hatz, CEO Dr. Thomas Hanke, CSO</b>
<b>Telephone</b>	<b>+49-931-35962-0</b>
<b>Fax</b>	<b>+49-931-35962-11</b>
<b>Email Address</b>	<b>info@tegenero.com</b>
<b>Internet Website</b>	<b>www.tegenero.com</b>
<b>Number of Employees</b>	<b>18</b>
<b>Founded (year)</b>	<b>2000</b>
<b>Type of Laboratory</b>	<b>S1</b>
<b>Areas of Activity</b>	<b>Immunotherapeutics</b>
<b>Annual Turnover</b>	<b>n.a.</b>
<b>Relevant R&amp;D Budget</b>	<b>n.a.</b>
<b>Biological Patents</b>	<b>n.a.</b>
<b>External Collaborations</b>	<b>Boehringer Ingelheim Pharma GmbH &amp; Co KG, University of Amsterdam, University of Würzburg, Swiss Institute for Asthma and Allergy Research, University of Cologne, University of Leiden</b>
<b>Requests for Further Collaboration</b>	<b>n.a.</b>

## ► Corporate Profile

TeGenero AG is a biopharmaceutical company dedicated to the identification and development of innovative, highly effective and broadly applicable immuno-therapeutic drugs. TeGenero's unique superagonistic monoclonal antibodies (SuperMAB™) are T cell stimulatory compounds that may serve as a groundbreaking treatment against autoimmune diseases and immune deficiencies associated with abnormalities in T lymphocyte number and function.

## ► TeGenero's SuperMAB paradigm generates novel antibodies for broad immunotherapeutic areas

TeGenero has developed a unique approach to balance T cell activation and expansion by triggering co-stimulatory CD receptors with novel monoclonal antibodies that convert "co-stimulatory" CD receptors into directly activating "stimulatory" CD receptors. With its most advanced product candidate TGN1412, a fully humanized CD28-SuperMAB™, TeGenero targets the most efficient CD receptor that co-stimulates T cells in combination with the TCR. TGN1412 bypasses the requirement for TCR signalling and activates T cells regardless of their TCR specificity. TGN1412 therefore represents the first universal T cell growth factor applicable for therapeutic purpose in the intact organism.

The principle of "superagonistic" stimulation of T cell CD receptors by specially developed monoclonal antibodies is not restricted to the CD28 molecule but can be transferred to other important immunomodulatory CD receptors. TeGenero therefore applies proprietary know-how gained with the CD28-SuperMAB™ to generate other T cell specific therapeutic antibody candidates.

## ► Clinical development strategy

TGN1412 is far advanced in pre-clinical development. It has shown unique *ex vivo* and *in vivo* T lymphocyte activating capacity and great therapeutic potential for a number of autoimmune/inflammatory and oncological diseases. A first-in-man clinical trial is projected to start in the second half of 2005.

*TGN1412 for the treatment of B-CLL:* Despite clinical benefits from chemo- or monoclonal antibody therapy, B cell chronic lymphocytic leukaemia (B-CLL) is still an incurable disease and the development of novel immunotherapies is highly requested. Based on *ex vivo* and *in vivo* model data, TGN1412 has the potential to overcome functional T cell deficiency in B-CLL patients to better fight infections and induce a long-term cellular anti-tumor response.

*TGN1412 for the treatment of rheumatoid arthritis (RA):* There is still a high medical need for efficacious and well-tolerated novel treatment options in autoimmune/inflammatory diseases such as RA. The pronounced anti-inflammatory effects of CD28-SuperMAB™ treatment in non-clinical models indicate that CD28-SuperMAB™ are capable of inhibiting clinical signs and pathophysiological mechanisms for a number of autoimmune/inflammatory diseases. TGN1412 is therefore a promising novel candidate to addressing the medical need in chronic inflammatory diseases, which require long-term therapy without severe side effects.

#### ► **Partnering Strategy**

TeGenero is interested to create commercially attractive alliances to leverage synergies from complementary expertise and secure funding for advanced drug development programs as well as further expansion of the pipeline.

#### ► **People**

##### *Key Personnel*

Benedikte Hatz, PhD, MBA, CEO, formerly BioM AG; Thomas Hanke, PhD, Priv.-Doz., CSO and founder, formerly University of Würzburg, University of California, Berkeley; Peter Müller, PhD, Head Non-Clinical Development, formerly Fresenius Biotech, Asta Medica, Paul-Ehrlich Institute

##### *Supervisory Board*

Prof. Jürgen Drews, MD, PhD, Independent chairman; Prof. Thomas Hünig, PhD, Founder, University of Würzburg; Prof. Patrick Baeuerle, PhD, CSO Micromet AG, representing HBM BioVentures

##### *Scientific and Development Board*

Prof. Dr. Ferdinand Breedveld, MD, University of Leiden; Thomas Kerkau, MD, Founder, University of Würzburg; Prof. Dr. Meuer, MD, University of Heidelberg



TeGenero



German Biotechs 2005